Mediators of Inflammation / 2013 / Article / Tab 5

Clinical Study

Human Leukocyte Antigen Class II Alleles (DQB1 and DRB1) as Predictors for Response to Interferon Therapy in HCV Genotype 4

Table 5

Frequencies and percentages of linkage between HLA alleles (haplotypes) in HCV patients and healthy group and in responder and nonresponder patients to combined treatment of interferon and ribavirin.

HaplotypesHCV Patients
( )
Healthy controls
( )
PCResponders
NonResponders
PC

DQB1*0201-DQB1*020228 (45.2%)20 (35.1%)0.07818 (47.4%)10 (50%)0.534
DQB1*0202-DQB1*02057 (11.3%)10 (17.5%)0.6956 (15.8%)1 (5%)0.226
DQB1*0204-DQB1*030114 (22.6%)12 (21.1%)1.0009 (23.7%)5 (25%)0.577
DQB1*0204-DQB1*03133 (4.8%)8 (14.1%)0.5670 (0%)3 (15 %)0.037#
DQB1*0309-DQB1*03137 (8.1%)6 (10.5%)1.0002 (5.3%)5 (25%)0.041#
DQB1*0309-DQB1*031925 (40.3%)18 (31.6%)0.08516 (42.1%)9 (45%)0.525
DQB1*0313-DQB1*03197 (11.3%)6 (10.5%)1.0002 (5.3%)5 (25%)0.041#
DQB1*0603-DQB1*062810 (16.2%)7 (12.3%)0.4478 (21.1%)2 (10%)0.250
DRB1*0301-DRB1*03188 (12.9%)2 (3.5%)0.0876 (14.6%)2 (9.5%)0.447
DRB1*0706-DRB1*07114 (6.5%)11 (19.3%)0.0842 (4.9%)2 (9.5%)0.417
DRB1*1301-DRB1*13287 (11.3%)10 (17.5%)0.6957 (17.1%)0 (0%)0.046#
DRB1*1301-DRB1*13617 (11.3%)12 (21.1%)0.2197 (17.1%)0 (0%)0.046#
DRB1*1301-DRB1*13697 (11.3%)15 (26.3%)0.0897 (17.1%)0 (0%)0.046#
DRB1*1328-DRB1*13617 (11.3%)3 (5.3%)0.3257 (17.1%)0 (0%)0.046#
DRB1*1328-DRB1*13697 (11.3%)9 (15.8%)0.7527 (17.1%)0 (0%)0.046#

Significant difference at PC ≤ 0.05; (corrected P after the Bonferroni correction) between responder and nonresponder patients to treatment. Each patient may have multiple suballeles or none at all, so that totals are not always equal to “ .”